United States Patent 8,568,747: Scope, Claim Strength, and Landscape for Enalapril Oral Reconstitution Powders
What is the claimed subject matter in US 8,568,747?
US 8,568,747 claims a specific oral-reconstitution powder and a performance-defined stability profile after reconstitution. The independent claim (claim 1) is defined by three elements:
- Composition (w/w):
- ~14% enalapril (or a pharmaceutically acceptable salt)
- ~85% mannitol
- ~1% colloidal silicon dioxide
- Reconstitution use case: reconstituted into an oral liquid formulation
- Post-reconstitution performance:
- the liquid is homogeneous
- the liquid is stable for at least 12 weeks
- under 25 ± 5°C and 55 ± 10% RH
Dependent claims then narrow the salt form, reconstitution vehicle, broader storage stability of the dry powder, and provide an explicit example dose.
Claim set as provided
| Claim |
Core scope limitation |
| 1 |
Powder composition: ~14% enalapril (or salt), ~85% mannitol, ~1% colloidal silicon dioxide; after reconstitution into oral liquid: homogeneous and stable ≥12 weeks at 25±5°C / 55±10% RH |
| 2 |
Enalapril salt is enalapril maleate |
| 3 |
Reconstitute in water |
| 4 |
Reconstitute in syrup |
| 5 |
Powder stable ≥6 months at ambient, accelerated, and refrigerated conditions |
| 6 |
Example pack: 150 mg enalapril, 890 mg mannitol, 10 mg colloidal silicon dioxide (total 1050 mg) |
How broad is the scope of claim 1?
Claim 1 is medium-narrow on composition and use, but broad on reconstitution form factors and reconstitution media.
Composition breadth: “about” percentages and generic salt language
- The claim does not require an exact formulation, only “about” ranges near:
- 14% enalapril (or salt)
- 85% mannitol
- 1% colloidal silicon dioxide
- It also covers “pharmaceutically acceptable salt thereof” for enalapril in claim 1, with claim 2 tightening to enalapril maleate.
From a freedom-to-operate angle, this means infringement arguments can still be made where:
- the active is enalaPRIL in a pharmaceutically acceptable salt form (not necessarily maleate) and
- excipients are the same classes and close ratios (mannitol + colloidal silicon dioxide).
Performance breadth: stability and homogeneity after reconstitution
Claim 1’s novelty and infringement leverage likely sit in the post-reconstitution stability requirement:
- ≥12 weeks
- homogeneous
- under 25±5°C and 55±10% RH
This turns claim scope from “simple excipient combination” into a property-limited formulation claim. Practically, it raises the evidentiary bar for both validity challenges and infringement proofs, since performance data must match the claim conditions.
Use breadth: oral liquid formulation by reconstitution
Claim 1 requires:
- a pharmaceutical powder
- reconstituted into an oral liquid
It does not constrain:
- the exact concentration of enalapril after reconstitution,
- the specific reconstitution volume,
- or the specific oral liquid type beyond being an oral liquid formulation,
except that dependent claims specify water (claim 3) and syrup (claim 4).
What do the dependent claims add?
Dependent claims reduce design-around space by pinning specific implementation choices.
Salt form (claim 2)
- Requires enalapril maleate.
- If a competitor uses a different enalapril salt, claim 2 may not read, but claim 1 can still potentially read (if the salt is “pharmaceutically acceptable”).
Reconstitution vehicle (claims 3 and 4)
- Claim 3 limits to reconstitution in water.
- Claim 4 limits to reconstitution in syrup.
- Claim 1 already covers reconstituted oral liquids generally; these dependent claims narrow to particular vehicles.
Dry powder stability (claim 5)
- Adds: powder stable ≥6 months at ambient, accelerated, and refrigerated conditions.
- This is a second stability axis: not just stability of the reconstituted liquid.
Example dosing (claim 6)
- Specifies an example unit composition:
- 150 mg enalapril
- 890 mg mannitol
- 10 mg colloidal silicon dioxide
- This is still “of the pharmaceutical powder of claim 1,” so it likely constrains to a dosage format (total 1050 mg powder).
Where is the likely novelty and what is the likely risk to competitors?
Based on the structure of claim 1, the likely novelty is the combination of:
1) a high-mannitol matrix with ~1% colloidal silicon dioxide,
2) enalapril at ~14% (or salt),
3) and a defined post-reconstitution stability showing homogeneity and stability for at least 12 weeks under specific temperature and humidity.
Competitors face two main infringement risk routes:
- Direct composition match: very close excipient system and ratios.
- Performance match: same or substantially similar composition that yields the claimed stability outcome under the claimed conditions.
How would a court likely interpret key terms?
This is claim-construction critical because both infringement and validity hinge on it.
“about” in composition percentages
- “About” provides tolerance; it reduces the ability to design around by small deviations.
- The risk for competitors is that “about 14%” and “about 85%” can still capture compositions that are not numerically identical but are within a reasonable tolerance.
“pharmaceutically acceptable salt”
- Covers more than just maleate unless the specification limits salts in the written description or enablement.
- If claim 1 is read broadly, a competitor using another accepted enalapril salt could still fall inside claim 1.
“homogenous and stable”
- “Homogeneous” implies no settling, separation, or unacceptable particulate issues after reconstitution.
- “Stable” requires retention of acceptable quality metrics (as a property) for at least 12 weeks at the defined conditions.
Stability condition limits
- The claim pins stability to 25±5°C and 55±10% RH for the reconstituted liquid.
- Competitors using different storage conditions might still infringe claim 1 if their product is stable under those conditions or if testing demonstrates stability within the band.
Patent landscape: where competitors likely face overlap
You provided only the claim text, not the patent’s filing history, assignee, or specification. That means the analysis below focuses on landscape inference grounded in claim scope and typical formulation patent patterns for enalapril oral powders.
Formulation patents that commonly overlap
Within the enalapril space, overlap risk typically comes from patents covering:
- enalapril in powder-to-liquid reconstitution formats (oral suspension or solution precursors),
- excipient systems controlling moisture uptake and dispersion stability,
- stability-driven excipient selection (mannitol as a bulking/drying matrix and colloidal silicon dioxide as a flow agent and moisture/aggregation modulator),
- and salt-form specific compositions (often maleate in enalapril products).
Given claim 1’s specific excipient package, landscape overlap is most likely where other patents claim:
- mannitol + colloidal silicon dioxide matrices for enalapril powders for oral reconstitution, and
- similar stability targets for the reconstituted liquid.
Design-around pathways and whether they likely work
| Design-around lever |
What it changes |
Likely outcome vs claim 1 |
| Replace colloidal silicon dioxide with another anti-caking excipient |
Excipient package |
May avoid claim 1 if the silicon dioxide is a required element; claim 1 requires “colloidal silicon dioxide” specifically |
| Change mannitol to another sugar alcohol/bulking agent |
Matrix |
High risk of non-infringement if mannitol is a required component |
| Use enalapril base instead of salt (or a salt outside “pharmaceutically acceptable”) |
Active form |
Risk depends on whether the substitute is still within “pharmaceutically acceptable salt” |
| Adjust ratios away from “about” ranges |
Composition |
Potentially avoids if outside the “about” tolerance; tolerance can be contested |
| Preserve reconstitution stability but under conditions outside the claim band |
Stability demonstration |
Risk remains if the product is stable within 25±5°C / 55±10% RH even if it is tested elsewhere |
| Change reconstitution vehicle only |
Use scenario |
Less likely to avoid claim 1 because claim 1 covers reconstituted oral liquids generally; may avoid claim 3 or 4 only |
Claim strength drivers for infringement and validity
Infringement strength drivers
- The claim is composition-defined and includes a performance-defined stability/homogeneity requirement.
- Dependent claim 6 locks to a specific unit dose composition. If a product matches that exact ratio, infringement becomes straightforward.
Validity vulnerability drivers
- Formulation claims can be challenged under obviousness-type arguments if:
- the excipient trio and their roles were known,
- and the stability outcome would be expected with routine optimization.
- However, the performance limitation (≥12 weeks at defined humidity/temperature) can mitigate obviousness if it is not taught or if unexpected results are shown.
Practical assessment: what claim 6 implies for product matching
Claim 6 provides a concrete formulation example:
- Total powder: 150 + 890 + 10 = 1050 mg
- Weight percentages from claim 6:
- enalapril: 150/1050 = 14.29%
- mannitol: 890/1050 = 84.76%
- colloidal silicon dioxide: 10/1050 = 0.95%
This maps tightly to claim 1’s “about 14% / 85% / 1%” ranges. A manufacturer using the claim 6 ratio likely meets claim 1 by composition alone, assuming reconstitution into oral liquid achieves the stability criteria.
Key Takeaways
- US 8,568,747 claim 1 is a formulation-and-performance claim covering enalapril (any pharmaceutically acceptable salt) at ~14% with ~85% mannitol and ~1% colloidal silicon dioxide, where the reconstituted oral liquid is homogeneous and stable ≥12 weeks at 25±5°C / 55±10% RH.
- Dependent claims narrow salt form to enalapril maleate (claim 2), reconstitution vehicle to water (claim 3) or syrup (claim 4), add dry powder stability ≥6 months (claim 5), and lock a specific example unit dose (claim 6).
- For competitors, the most direct infringement risk is using the same excipient trio and ratios coupled with a reconstituted liquid meeting the 12-week stability/homogeneity requirement.
- The strongest design-around levers are to change the required excipient elements (especially colloidal silicon dioxide or mannitol) or to move outside the composition tolerances so the “about” ranges are not met, while also avoiding matching the claimed stability behavior.
FAQs
1) Does claim 1 require enalapril maleate specifically?
No. Claim 1 covers enalapril or a pharmaceutically acceptable salt. Claim 2 specifically requires enalapril maleate.
2) What makes claim 1 more than a basic excipient combination?
Claim 1 requires the reconstituted oral liquid to be homogeneous and stable for at least 12 weeks at 25±5°C and 55±10% RH.
3) If a product is stable at other temperatures but not at 25±5°C / 55±10% RH, does it avoid claim 1?
The claim is framed around stability at the specified conditions; infringement and proof will hinge on whether stability holds for at least 12 weeks under those parameters.
4) Would changing the reconstitution medium from water to syrup avoid infringement?
Not by itself. Claim 1 covers reconstituted oral liquids generally; claim 3 and claim 4 narrow to water and syrup, respectively.
5) Does claim 6 represent an additional independent invention point?
No. Claim 6 is a dependent claim that locks a specific example composition, mapping tightly to claim 1’s percentage ranges.
References
[1] United States Patent 8,568,747 (claims as provided by user).
